Yaru Zhao

Closest collaborators

The 13 strongest of 13 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Christopher Heeschen · 4 shared papers, 2023–2025 · strength 0.82
   • Paper CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. DOI 10.1002/adhm.202500546↗
   • Paper Liquid biopsy in pancreatic cancer - Current perspective and future outlook. DOI 10.1016/j.bbcan.2023.188868↗
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
2. Jiajia Tang · 3 shared papers, 2023–2025 · strength 0.55
   • Paper Liquid biopsy in pancreatic cancer - Current perspective and future outlook. DOI 10.1016/j.bbcan.2023.188868↗
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
3. Ke Jiang · 2 shared papers, 2023–2024 · strength 0.37
   • Paper Liquid biopsy in pancreatic cancer - Current perspective and future outlook. DOI 10.1016/j.bbcan.2023.188868↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
4. Elisabetta Fenocchio · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
5. Da Fu · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
6. Berina Šabanović · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
7. Quan Zheng · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
8. Chenlei Wen · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
9. Baiyong Shen · 2 shared papers, 2024–2025 · strength 0.33
   • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
   • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
10. Qi Wang · 2 shared papers, 2024–2025 · strength 0.33
    • Paper Protocol for the creation and utilization of 3D pancreatic cancer models from circulating tumor cells. DOI 10.1016/j.xpro.2025.103635↗
    • Paper CTC-derived pancreatic cancer models serve as research tools and are suitable for precision medicine approaches. DOI 10.1016/j.xcrm.2024.101692↗
11. Hua Jiang · 1 shared paper, 2025 · strength 0.27
    • Paper CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. DOI 10.1002/adhm.202500546↗
12. Zonghai Li · 1 shared paper, 2025 · strength 0.27
    • Paper CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. DOI 10.1002/adhm.202500546↗
13. Yue Qing · 1 shared paper, 2025 · strength 0.27
    • Paper CLDN18.2 CAR-derived Extracellular Vesicle Immunotherapy Improves Outcome in Murine Pancreatic Cancer. DOI 10.1002/adhm.202500546↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.